Open AccessAcetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial
Author(s) -
Davoud Eskandari,
Ding Zou,
Ludger Grote,
Erik Hoff,
Jan Hedner
Publication year - 2018
Publication title -
journal of clinical sleep medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 92
eISSN - 1550-9397
pISSN - 1550-9389
DOI - 10.5664/jcsm.6968
Subject(s) - medicine , acetazolamide , obstructive sleep apnea , randomized controlled trial , blood pressure , sleep disordered breathing , sleep apnea , apnea , anesthesia , sleep (system call) , breathing , cardiology , computer science , operating system
The carbonic anhydrase inhibitor acetazolamide (AZT) modulates blood pressure at high altitude and reduces sleep-disordered breathing in patients with obstructive sleep apnea (OSA). We aimed to investigate the treatment effect of AZT and in combination with continuous positive airway pressure (CPAP) on blood pressure in patients with hypertension and OSA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom